Stroke Risk among Elderly and non-Elderly Users of Typical vs. Atypical Antipsychotics: A Real-World Study from a US Health Insurance Claims Database
=============

<img src="https://img.shields.io/badge/Study%20Status-Complete-orange.svg" alt="Study Status: Complete">

- Analytics use case(s): **Population-Level Estimation**
- Study type: **Clinical Application**
- Tags: **-**
- Study lead: **Dan Fife, Clair Blacketer, Karl Knight, James Weaver**
- Study lead forums tag: **[clairblacketer](https://forums.ohdsi.org/u/clairblacketer/), [jweave17](https://forums.ohdsi.org/u/jweave17/)**
- Study start date: **December 29, 2018**
- Study end date: **July 31, 2019**
- Protocol: **[Protocol](https://github.com/ohdsi-studies/StrokeRiskInElderlyApUsers/tree/master/documents)**
- Publications: **-**
- Results explorer: **[StrokeRiskInElderlyApUsers](https://data.ohdsi.org/StrokeRiskInElderlyApUsers/), [StrokeRiskInNonElderlyApUsers](https://data.ohdsi.org/StrokeRiskInNonElderlyApUsers/)**

This study estimated stroke risk associated with new exposure to haloperidol, or any typical vs. atypical antipsychotic, among patients aged â‰¥65 years and among patients aged 18-64 years regardless of dementia status.
